Go Pro
→ MILLIONAIRE MASTERCLASS INVITE: Altucher (From Paradigm Press) (Ad)tc pixel Free ARDS Stock Alerts

Aridis Pharmaceuticals (ARDS) Competitors

Aridis Pharmaceuticals logo
$0.0001 0.00 (0.00%)
As of 03:10 PM Eastern
Compare

ARDS vs. VRPX, BPTH, SYRS, TRVN, and NAVB

Should you buy Aridis Pharmaceuticals stock or one of its competitors? Aridis Pharmaceuticals's main competitors and comparable companies include Virpax Pharmaceuticals (VRPX), Bio-Path (BPTH), Syros Pharmaceuticals (SYRS), Trevena (TRVN), and Navidea Biopharmaceuticals (NAVB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Aridis Pharmaceuticals compare to Virpax Pharmaceuticals?

Virpax Pharmaceuticals (NASDAQ:VRPX) and Aridis Pharmaceuticals (NASDAQ:ARDS) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, media sentiment, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends.

32.2% of Virpax Pharmaceuticals shares are held by institutional investors. Comparatively, 9.6% of Aridis Pharmaceuticals shares are held by institutional investors. 3.7% of Virpax Pharmaceuticals shares are held by insiders. Comparatively, 5.5% of Aridis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Virpax Pharmaceuticals has a beta of -16.55, indicating that its stock price is 1,755% less volatile than the broader market. Comparatively, Aridis Pharmaceuticals has a beta of 49.95, indicating that its stock price is 4,895% more volatile than the broader market.

Aridis Pharmaceuticals' return on equity of 0.00% beat Virpax Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Virpax PharmaceuticalsN/A -1,554.34% -338.29%
Aridis Pharmaceuticals N/A N/A N/A

Virpax Pharmaceuticals is trading at a lower price-to-earnings ratio than Aridis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Virpax PharmaceuticalsN/AN/A-$15.19M-$123.25N/A
Aridis PharmaceuticalsN/AN/A-$30.37M$0.310.00

In the previous week, Virpax Pharmaceuticals' average media sentiment score of 0.00 equaled Aridis Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Virpax Pharmaceuticals Neutral
Aridis Pharmaceuticals Neutral

Summary

Aridis Pharmaceuticals beats Virpax Pharmaceuticals on 6 of the 8 factors compared between the two stocks.

How does Aridis Pharmaceuticals compare to Bio-Path?

Aridis Pharmaceuticals (NASDAQ:ARDS) and Bio-Path (NASDAQ:BPTH) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, media sentiment, dividends, profitability and risk.

Bio-Path is trading at a lower price-to-earnings ratio than Aridis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aridis PharmaceuticalsN/AN/A-$30.37M$0.310.00
Bio-PathN/AN/A-$16.08M-$1.09N/A

Aridis Pharmaceuticals has a beta of 49.95, meaning that its share price is 4,895% more volatile than the broader market. Comparatively, Bio-Path has a beta of -0.53, meaning that its share price is 153% less volatile than the broader market.

In the previous week, Aridis Pharmaceuticals' average media sentiment score of 0.00 equaled Bio-Path'saverage media sentiment score.

Company Overall Sentiment
Aridis Pharmaceuticals Neutral
Bio-Path Neutral

Aridis Pharmaceuticals' return on equity of 0.00% beat Bio-Path's return on equity.

Company Net Margins Return on Equity Return on Assets
Aridis PharmaceuticalsN/A N/A N/A
Bio-Path N/A -2,842.40%-337.48%

9.6% of Aridis Pharmaceuticals shares are held by institutional investors. Comparatively, 5.7% of Bio-Path shares are held by institutional investors. 5.5% of Aridis Pharmaceuticals shares are held by insiders. Comparatively, 0.7% of Bio-Path shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Aridis Pharmaceuticals beats Bio-Path on 7 of the 8 factors compared between the two stocks.

How does Aridis Pharmaceuticals compare to Syros Pharmaceuticals?

Syros Pharmaceuticals (NASDAQ:SYRS) and Aridis Pharmaceuticals (NASDAQ:ARDS) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

Aridis Pharmaceuticals has lower revenue, but higher earnings than Syros Pharmaceuticals. Syros Pharmaceuticals is trading at a lower price-to-earnings ratio than Aridis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Syros Pharmaceuticals$386K0.03-$164.57M-$3.03N/A
Aridis PharmaceuticalsN/AN/A-$30.37M$0.310.00

Syros Pharmaceuticals has a beta of 1.31, meaning that its stock price is 31% more volatile than the broader market. Comparatively, Aridis Pharmaceuticals has a beta of 49.95, meaning that its stock price is 4,895% more volatile than the broader market.

In the previous week, Syros Pharmaceuticals' average media sentiment score of 0.00 equaled Aridis Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Syros Pharmaceuticals Neutral
Aridis Pharmaceuticals Neutral

91.5% of Syros Pharmaceuticals shares are held by institutional investors. Comparatively, 9.6% of Aridis Pharmaceuticals shares are held by institutional investors. 12.3% of Syros Pharmaceuticals shares are held by company insiders. Comparatively, 5.5% of Aridis Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Aridis Pharmaceuticals' return on equity of 0.00% beat Syros Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Syros PharmaceuticalsN/A -3,369.56% -97.04%
Aridis Pharmaceuticals N/A N/A N/A

Summary

Aridis Pharmaceuticals beats Syros Pharmaceuticals on 6 of the 9 factors compared between the two stocks.

How does Aridis Pharmaceuticals compare to Trevena?

Aridis Pharmaceuticals (NASDAQ:ARDS) and Trevena (NASDAQ:TRVN) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

Company Net Margins Return on Equity Return on Assets
Aridis PharmaceuticalsN/A N/A N/A
Trevena N/A N/A -119.55%

Aridis Pharmaceuticals has higher earnings, but lower revenue than Trevena. Trevena is trading at a lower price-to-earnings ratio than Aridis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aridis PharmaceuticalsN/AN/A-$30.37M$0.310.00
Trevena$443K0.02-$40.29M-$47.04N/A

Aridis Pharmaceuticals has a beta of 49.95, meaning that its share price is 4,895% more volatile than the broader market. Comparatively, Trevena has a beta of -0.55, meaning that its share price is 155% less volatile than the broader market.

9.6% of Aridis Pharmaceuticals shares are owned by institutional investors. Comparatively, 13.6% of Trevena shares are owned by institutional investors. 5.5% of Aridis Pharmaceuticals shares are owned by insiders. Comparatively, 2.7% of Trevena shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Trevena had 1 more articles in the media than Aridis Pharmaceuticals. MarketBeat recorded 1 mentions for Trevena and 0 mentions for Aridis Pharmaceuticals. Trevena's average media sentiment score of 0.37 beat Aridis Pharmaceuticals' score of 0.00 indicating that Trevena is being referred to more favorably in the news media.

Company Overall Sentiment
Aridis Pharmaceuticals Neutral
Trevena Neutral

Summary

Aridis Pharmaceuticals beats Trevena on 6 of the 10 factors compared between the two stocks.

How does Aridis Pharmaceuticals compare to Navidea Biopharmaceuticals?

Navidea Biopharmaceuticals (NYSE:NAVB) and Aridis Pharmaceuticals (NASDAQ:ARDS) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, media sentiment, institutional ownership and valuation.

Company Net Margins Return on Equity Return on Assets
Navidea BiopharmaceuticalsN/A N/A N/A
Aridis Pharmaceuticals N/A N/A N/A

In the previous week, Navidea Biopharmaceuticals' average media sentiment score of 0.00 equaled Aridis Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Navidea Biopharmaceuticals Neutral
Aridis Pharmaceuticals Neutral

Navidea Biopharmaceuticals has a beta of 1.76, indicating that its share price is 76% more volatile than the broader market. Comparatively, Aridis Pharmaceuticals has a beta of 49.95, indicating that its share price is 4,895% more volatile than the broader market.

Navidea Biopharmaceuticals has higher revenue and earnings than Aridis Pharmaceuticals. Navidea Biopharmaceuticals is trading at a lower price-to-earnings ratio than Aridis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Navidea Biopharmaceuticals$8.13K0.00-$15.18M-$0.21N/A
Aridis PharmaceuticalsN/AN/A-$30.37M$0.310.00

0.0% of Navidea Biopharmaceuticals shares are owned by institutional investors. Comparatively, 9.6% of Aridis Pharmaceuticals shares are owned by institutional investors. 43.7% of Navidea Biopharmaceuticals shares are owned by insiders. Comparatively, 5.5% of Aridis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Aridis Pharmaceuticals beats Navidea Biopharmaceuticals on 4 of the 7 factors compared between the two stocks.

Get Aridis Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for ARDS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARDS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ARDS vs. The Competition

Export
MetricAridis PharmaceuticalsPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$5K$12.53B$7.26B$13.10B
Dividend YieldN/A2.63%2.52%12.57%
P/E Ratio0.00792.39274.9825.77
Price / SalesN/A850.84679.2597.61
Price / CashN/A88.6477.8052.76
Price / BookN/A10.6910.526.34
Net Income-$30.37M$2.83B$3.49B$360.00M
7 Day PerformanceN/A-0.69%-1.08%-0.11%
1 Month PerformanceN/A-1.10%-3.39%-3.42%
1 Year PerformanceN/A2.10%15.08%5.46%

Aridis Pharmaceuticals Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ARDS
Aridis Pharmaceuticals
N/A$0.00
flat		N/A-94.1%$5KN/A0.0030
VRPX
Virpax Pharmaceuticals
N/A$0.01
flat		N/AN/A$14KN/AN/A7
BPTH
Bio-Path
N/A$0.00
+100.0%		N/A-99.2%$11KN/AN/A10
SYRS
Syros Pharmaceuticals
N/A$0.00
-96.7%		N/A+300.0%$11K$386KN/A120
TRVN
Trevena
N/A$0.01
flat		N/A+12.0%$11K$443KN/A40

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:ARDS) was last updated on 9/24/2026 by MarketBeat.com Staff.
From Our Partners
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...
Porter & Company | Sponsoredtc pixel
Shocking new footage just released
Gerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...
Digest Publishing | Sponsoredtc pixel
The retirement stock I'd buy before Nvidia today
In 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...
Chaikin Analytics | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
NASA's ISS Replacement Could Go to This Tiny Space Firm
NASA has commissioned SpaceX to decommission the $150 billion International Space Station, but the contract to...
Behind the Markets | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
AI Panic: Sell now or wait?
Bank of America, Goldman Sachs, and Morgan Stanley have reportedly warned private clients about a coming stock...
TradeSmith | Sponsoredtc pixel